RESEARCH NOTE

1

- 2 Evolution of SARS-CoV-2 immune responses in nursing home residents following
- 3 full dose of the Comirnaty® COVID-19 vaccine
- 4 Estela Giménez^{1†}, Juan Alberola^{2†}, Ignacio Torres¹, Eliseo Albert¹, María Jesús
- 5 Alcaraz¹, Pilar Botija³, Paula Amat⁴, María José Remigia⁴, María José Beltrán⁵, Celia
- 6 Rodado⁶, Dixie Huntley¹, Beatriz Olea¹, and David Navarro^{1,2*}
- ¹Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute,
- 8 Valencia, Spain.
- 9 ²Department of Microbiology, School of Medicine, University of Valencia, Valencia,
- 10 Spain
- 11 ³Dirección de Atención Primaria, Departamento de Salud Clínico-Malvarrosa,
- 12 Hospital Clínico Universitario de Valencia, Valencia, Spain.
- 13 ⁴Hematology Service Clinic University Hospital, INCLIVA Health Research Institute,
- 14 Valencia, Spain.
- 15 ⁵Dirección de Enfermería, Departamento de Salud Clínico-Malvarrosa, Hospital
- 16 Clínico Universitario de Valencia, Valencia, Spain.
- 17 ⁶Comisión Departamental de control de Residencias. Departamento de Salud València
- 18 Clínico Malvarrosa.

20

- †Both authors contributed equally to the present work.
- 21 *Correspondence: David Navarro, Microbiology Service, Hospital Clínico
- 22 Universitario, Instituto de Investigación INCLIVA, Valencia, and Department of
- 23 Microbiology, University of Valencia, Valencia, Spain. Av. Blasco Ibáñez 17, 46010

- 24 Valencia, Spain. Phone: 34(96)1973500; Fax: 34(96)3864173; E-mail:
- david.navarro@uv.es.
- 26 Running title: Immunogenicity of Comirnaty® COVID-19 vaccine in nursing home
- 27 residents.
- 28 ABSTRACT
- 29 **Objectives:** There is scarce information as to the durability of immune responses
- 30 elicited by the Comirnaty® COVID-19 vaccine in nursing home residents. Here, we
- 31 assessed SARS-CoV-2-Spike (S)-targeted antibody and functional T cell responses at
- around 6 months after complete vaccination.
- 33 **Methods:** The sample comprised 46 residents (34 females; age, 60-100 years), of whom
- 34 10 had COVID-19 prior to vaccination. Baseline (median of 17.5 days after vaccination)
- and follow-up (median, 195 days) plasma specimens were available for quantitation of
- 36 SARS-CoV-2-S antibodies and enumeration of SARS-CoV-2-S-reactive IFN-γ CD4⁺
- and CD8⁺ T cells by flow cytometry.
- 38 **Results:** In total, 44/45 participants had detectable SARS-CoV-2-S antibodies at
- 39 follow-up. Overall, antibody levels were found to decrease (median, 4.8 fold).
- 40 Antibodies waning was more frequent (P<0.001) in SARS-CoV-2 naïve (29/35) than in
- 41 recovered (1/10) residents. SARS-CoV-2-S IFN-γ CD8⁺ T cells were detected in 33/46
- 42 and 24/46 at baseline and follow-up, respectively. The figures for CD4⁺ T cell
- 43 counterparts were 12/46 and 30/46. Detectable SARS-CoV-2 IFN-γ CD8⁺ and CD4⁺ T
- 44 cell responses at follow-up were more common in recovered (8/10 and 7/10,
- 45 respectively) than in naïve residents (9/36 and 25/36, respectively). For those with
- 46 detectable responses at both time points, SARS-CoV-2-S IFN-γ CD8⁺ T cell frequencies

48

49

51

52

53

54

55

56

57

59

60

61

62

63

65

67

68

69

decreased significantly (P=0.001) over time whereas the opposite (P=0.01) was observed in CD4⁺ T cells. Conclusion: Almost all residents displayed detectable SARS-CoV-2-S-reactive 50 antibodies and T cell responses, respectively, by around 6 months after complete vaccination with Comirnaty® COVID-19 vaccine, albeit generally waning in magnitude over time. **Keywords:** SARS-CoV-2, Comirnaty® COVID-19 vaccine, SARS-CoV-2-S antibodies; SARS-CoV-2-S T cells, Nursing home residents. **INTRODUCTION** Real-world experience has shown mRNA COVID-19 vaccines to be effective in reducing incidence of both asymptomatic and symptomatic SARS-CoV-2 infections and 58 related deaths in nursing home residents [1], congruent with their ability to elicit robust virus-specific T and B cell immune responses in this population group [2-4]. Nevertheless, maintaining seemingly protective immune responses in these individuals over time may be compromised by the concurrence of older age, frailty and comorbidities. To shed light on this issue, here we assessed SARS-CoV-2-Spike (S)targeted antibody and functional T cell responses at around 6 months after vaccination 64 with Comirnaty® (Pfizer–BioNTech) in a previously recruited cohort [2]. MATERIAL AND METHODS 66 Participants and study design Out of 53 nursing home residents enrolled in a previous study [2] with data on B and T cell immunity at a median of 17.5 days (range, 14–35 days) after second vaccine dose (baseline sample), 46 (44 females; median age, 89 years; range, 60–100; Supplementary 70 Table 1) were reassessed (follow-up sample) at a median of 195 days (range, 179–195 71 days). The remaining 7 patients either died (n=4; in no case attributable to COVID-19) 72 or lacked the follow-up specimen (n=3). Blood specimens were collected in sodium 73 heparin tubes (Beckton Dickinson, U.K. Ltd., UK). Informed consent was obtained 74 from participants. The study was approved by the Hospital Clínico Universitario 75 INCLIVA Research Ethics Committee (February, 2021). 76 **Immunological assays** 77 Total antibodies (IgG and IgM) against SARS-CoV-2-S protein receptor binding 78 domain (RBD) and the nucleoprotein (N) were measured by Roche Elecsys® 79 electrochemiluminescence sandwich immunoassays (Roche Diagnostics, Pleasanton, 80 CA, USA). Cryopreserved plasma (-20 °C) specimens were thawed and assayed in 81 singlets within 15 days after collection. Plasma specimens were diluted (1/10) for 82 antibody quantitation when appropriate. SARS \square CoV \square 2 \square S-reactive 83 IFN₇ □ producing □ CD8⁺ and CD4⁺ T cells were enumerated in whole blood by flow 84 cytometry for **ICS** (BD Fastimmune, BD ☐ Beckton Dickinson and 85 Company Biosciences, San Jose, CA) as previously described [2]. 86 Statistical methods Differences between medians were compared using the Mann-Whitney U-test or Wilcoxon test for unpaired and paired data, when appropriate. The Spearman rank test

- 87
- 88
- 89 was used for correlation analyses between continuous variables. Two-sided exact P-
- 90 values were reported. A P-value <0.05 was considered statistically significant. The
- 91 analyses were performed using SPSS version 20.0 (SPSS, Chicago, IL, USA).

RESULTS

92

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

SARS-CoV-2 infectious status of participants Of the 46 residents, 10 (21.7%) had evidence of SARS-CoV-2 infection at baseline, as determined by both RT-PCR on nasopharyngeal specimens and detection of N-specific antibodies. No additional residents developed N-specific antibodies between sampling times. **SARS-CoV-2-S-specific antibodies** Data on SARS-CoV-2-RBD antibody levels were available for 45 participants. All 43 residents who tested positive at baseline also displayed detectable responses at followup, although overall, antibody levels were found to decrease significantly, by a median of 4.8 fold (range, 1.1–39) [median of 2,249 IU/ml at baseline vs. median 307 IU/ml at follow-up, P<0.001 (Figure 1A)]. One of the two remaining residents developed SARS-CoV-2-S-specific antibodies (8 IU/ml) between sampling times. Antibodies waning was documented more frequently (P<0.001) in SARS-CoV-2 naïve (29/35) than in recovered (1/10) residents (Figure 1B). SARS-CoV-2-S-specific T cells Data on T cell responses were available for 46 participants. Overall, detectable SARS-CoV-2-S IFN-γ T cells (either CD8⁺, CD4⁺ or both) were documented in 82.6 % (38/46) and 73.9% (34/46) of residents at baseline and follow-up, respectively (P=0.01). The corresponding figures for SARS-CoV-2-S IFN-γ CD8⁺ T cells were 72% (33/46) and 52.1% (24/46). As shown in Figure 2A, 8 of 13 residents testing negative at baseline later acquired detectable responses, albeit at low frequencies (median, 0.08%; range, 0.01–0.21%), whereas SARS-CoV-2-S IFN-γ CD8⁺ T cells were no longer detectable at follow-up in 16 out of 33 residents who tested positive at baseline. SARS-CoV-2-S IFN-γ CD4⁺ T cells were detected in 26% (12/46) and 65.2% (30/46) of residents at

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

baseline and follow-up, respectively. Nineteen participants developed CD4⁺ T cell responses between testing time points (median, 0.1%; range, 0.03-1.14%), whereas one out of 12 with detectable responses at baseline had lost this at follow-up (Figure 2B). The likelihood of having detectable SARS-CoV-2 IFN-γ CD8⁺ and CD4⁺ T at follow-up was higher (P=0.03 and P=0.5) in SARS-CoV-2 recovered (8/10 and 7/10, respectively) than in naïve residents (9/36 and 25/36, respectively). For those with detectable responses at both time points, overall, SARS-CoV-2-S IFN-γ CD8⁺ T cell frequencies decreased significantly (P=0.001) over time whereas the opposite (P=0.01) was seen for CD4⁺ T cells (Figure 2C). Interestingly, the resident lacking anti-RBD antibodies at follow-up had detectable SARS-CoV-2-S CD4⁺ T cell responses. Supplementary Table 2 shows the combined results for all immunological parameters. No correlation was found between anti-RBD antibody levels and SARS-CoV-2-S IFN-y $CD4^{+}$ (Rho=-0.015; P=0.94) and $CD8^{+}$ (Rho:-0.18; P=0.87) T cells. **DISCUSSION** The main findings of the current study are as follows. First, while SARS-CoV-2-RBD antibodies, which correlate strongly with neutralizing antibody titers [5], were detectable in 97.7% (44/45) of nursing home residents by around 6 months after full vaccination with Comirnaty®, their levels declined significantly over time (a median of 5-fold); second, RBD-reactive antibody waning was rather frequent (29/35) in SARS-CoV-2 naïve, but uncommon (1/10) in recovered residents, who overall maintained high antibody levels at follow-up. The above observations were not unexpected as they have also been made in other population groups, including younger individuals seemingly with few or no comorbidities [6-8], at comparable timeframes [7,8] after full vaccination with mRNA vaccines; third, a large percentage of residents (34/46; 73.9%)

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

had detectable SARS-CoV-2-S IFN-y T cells (either CD8⁺, CD4⁺ or both) at follow-up, SARS-CoV-2-S IFN-γ CD4⁺ T cell responses being more frequently documented than their CD8⁺ T cells counterparts. Interestingly, recovered COVID-19 residents were more likely to display both CD8⁺ and CD4⁺ detectable responses at follow-up than naïve ones. Finally, for those with detectable responses at both sampling times, SARS-CoV-2-S IFN-γ CD8⁺ T cell frequencies decreased significantly, whereas the opposite was observed for CD4⁺ T cells. In this regard, collectively, the above data suggested that SARS-CoV-2-S IFN-y CD4⁺ T cells may develop later than CD8⁺ T cells in nursing home residents. Limitations of the current study are the relatively small sample size and lack of a control group; regarding the latter, most of the 17 controls included in our previous study [2] were unfortunately not available for follow-up sampling. Secondly, neutralization assays were not carried out. In summary, our data revealed that a large percentage of nursing home residents displayed detectable SARS-CoV-2-S-reactive antibodies and T cell responses, respectively, by around 6 months after complete vaccination with Comirnaty® COVID-19 vaccine, although these generally declined over time. Whether these mid-term immune responses suffice to prevent COVID-19 remains to be determined. Our data also suggested that a booster (third) dose, which has been proposed for elderly people [9,10] may be delayed beyond 6 months in fully vaccinated COVID-19 recovered residents. ACKNOWLEDGMENTS We are grateful to all personnel who work at nursing home residences affiliated to the Clínico-Malvarrosa Health Department and at Clinic University Hospital, in particular to those at the Microbiology laboratory, for their commitment in the fight against

- 165 COVID-19. Ignacio Torres holds a Río Hortega Contract (CM20/00090) from the
- 166 Carlos III Health Institute. Eliseo Albert holds a Juan Rodés Contract (JR20/00011)
- 167 from the Carlos III Health Institute. Estela Giménez holds a Juan Rodés Contract
- 168 (JR18/00053) from the Carlos III Health Institute.

169 FINANCIAL SUPPORT

171

173

170 This work received no public or private funds.

CONFLICTS OF INTEREST

172 The authors declare no conflicts of interest.

AUTHOR CONTRIBUTIONS

- EG, JA, IT, EA, MJA, PA, MJR, DH and BO: Methodology and data validation. PB,
- 175 MJB, CR: in charge of implementing public health policies to combat SARS-CoV-2
- 176 epidemic at nursing home residences affiliated to the Clínico-Malvarrosa Health
- 177 Department. DN: Conceptualization, supervision, writing the original draft. All authors
- 178 reviewed the original draft.

179 **REFERENCES**

- 180 1. White EM, Yang X, Blackman C, Feifer RA, Gravenstein S, Mor V. Incident SARS-
- 181 CoV-2 Infection among mRNA-Vaccinated and Unvaccinated Nursing Home
- 182 Residents. N Engl J Med 2021;385:474-476.
- 2. Torres I, Albert E, Giménez E, Alcaraz MJ, Botija P, Amat P, et al. B and T cell
- 184 immune responses elicited by the Comirnaty COVID-19 vaccine in nursing-home
- residents. Clin Microbiol Infect 2021;S1198-743X(21)00332-3.

- 186 3. Salmerón Ríos S, Mas Romero M, Cortés Zamora EB, Tabernero Sahuquillo MT,
- Romero Rizos L, Sánchez-Jurado PM, et al. Immunogenicity of the BNT162b2 vaccine
- in frail or disabled nursing home residents: COVID-A study. J Am Geriatr Soc
- 189 2021;69:1441-1447.
- 4. Blain H, Tuaillon E, Gamon L, Pisoni A, Miot S, Rolland Y, et al. Antibody response
- 191 after one and two jabs of the BNT162b2 vaccine in nursing home residents: The
- 192 CONsort-19 study. Allergy 2021 Jul 19. doi: 10.1111/all.15007.
- 5. Higgins V, Fabros A, Kulasingam V. Quantitative measurement of anti-SARS-CoV-2
- antibodies: Analytical and clinical evaluation. J Clin Microbiol 2021;59:e03149-20.
- 6. Naaber P, Tserel L, Kangro K, Sepp E, Jürjenson V, Adamson A, et al. Dynamics of
- antibody response to BNT162b2 vaccine after six months: a longitudinal prospective
- study. Lancet Reg Health Eur 2021 Sep 6:100208.
- 198 7. Tré-Hardy M, Cupaiolo R, Wilmet A, Antoine-Moussiaux T, Della Vecchia A,
- 199 Horeanga A, et al. Six-month interim analysis of ongoing immunogenicity surveillance
- 200 of the mRNA-1273 vaccine in healthcare workers: A third dose is expected. J Infect
- 201 2021:S0163-4453(21)00433-3.
- 202 8. Dimeglio C, Herin F, Miedougé M, Da-Silva I, Porcheron M, Martin-Blondel G, et
- 203 al. One year later: SARS-CoV-2 immune response and vaccination of healthcare
- 204 workers post-infection. J Infect 2021;83:381-412.
- 9. Soiza RL, Scicluna C, Thomson EC. Efficacy and safety of COVID-19 vaccines in
- 206 older people. Age Ageing 2021;50:279-283.

- 207 10. Krause PR, Fleming TR, Peto R, Longini IM, Figueroa JP, Sterne JAC, et al.
- 208 Considerations in boosting COVID-19 vaccine immune responses. Lancet, 2021.
- 209 DOI:https://doi.org/10.1016/S0140-6736(21)02046-8
- 210 11. Callaway E. COVID vaccine boosters: the most important questions. Nature. 2021
- 211 Aug;596(7871):178-180.
- 212 12. Mattiuzzo G, Bentley EM, Hassall M, Routley S, Richardson S, Bernasconi V, et al.
- 213 Establishment of the WHO International Standard and Reference Panel for anti-SARS-
- 214 CoV-2 antibody. WHO/BS/2020.2403, December 10, 2020.

215 FIGURE LEGENDS

- Figure 1. (A) SARS-CoV-2-S (RBD) plasma antibody (IgG and IgM) levels as
- 217 measured by Roche Elecsys® Anti-SARS-CoV-2-S immunoassay in nursing home
- 218 residents with (recovered) or without (naïve) documented prior SARS-CoV-2 infection
- at baseline (median, 17.5 days) and follow-up (median, 195 days) after complete
- 220 Comirnaty® COVID-19 vaccination. The limit of detection of the assay is 0.4 IU/ml
- and its quantification range is between 0.8 and 250 IU/ml. Plasma specimens were
- 222 further diluted (1/10) for antibody quantitation when appropriate. The assay is calibrated
- with the first WHO International Standard and Reference Panel for anti-SARS-CoV-2
- 224 antibody [12]. Bars represent median levels. (B) Individual kinetics of SARS-CoV-2-S
- 225 (RBD) plasma antibodies in recovered and naïve nursing home residents. P-values for
- comparisons are shown (ns; not significant).
- **Figure 2**. SARS-CoV-2-S-reactive IFN-γ-producing T cell levels in SARS-CoV-2
- 228 naïve and or recovered nursing home residents measured at baseline (median, 17.5 days)
- and follow-up (median, 195 days) after complete Comirnaty® COVID-19 vaccination.
- Briefly, heparinized whole blood $(0.5 \square \text{ml})$ was simultaneously stimulated for $6 \square \text{h}$ with

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

two sets of 15 mer overlapping peptides (11 mer overlap) encompassing the SARS CoV 2 Spike (S) glycoprotein (S1, 158 peptides and S2, 157 peptides) at a concentration of 1 □µg/ml per peptide, in the presence of 1 □µg/ml of costimulatory monoclonal antibodies (mAbs) to CD28 and CD49d. Peptide mixes were obtained from JPT peptide Technologies GmbH (Berlin, Germany). Samples mock-stimulated with phosphate buffered saline (PBS)/dimethyl sulfoxide and costimulatory antibodies were run in parallel. Brefeldin A (10 \(\pi \mu g/ml \)) was added for the last 4 \(\pi \) h of incubation. Blood was then lysed (BD FACS lysing solution) and frozen at -80°C until tested. On the day of testing, stimulated blood was thawed at 37°C, washed, permeabilized (BD permeabilizing solution) and stained with a combination of labeled mAbs (anti \Box IFNy \Box FITC, anti \Box CD4 \Box PE, anti \Box CD8 \Box PerCP \Box Cy5.5, and anti \Box CD3 \Box APC) for 1 □ h at room temperature. Appropriate positive (phytohemagglutinin) and isotype controls were used. Cells were then washed, resuspended in 200 □ µL of 1% paraformaldehyde in PBS, and analyzed within 2 □ h on an FACSCanto flow cytometer using DIVA v8 software (BD Biosciences Immunocytometry Systems, San Jose, CA). CD3⁺/CD8⁺ or CD3⁺/CD4⁺ events were gated and then analyzed for IFN □ γ production. All data were corrected for background IFN-γ production (FITC-labelled isotype control antibody) and expressed as a percentage of total CD8⁺ or CD4⁺ T cells. (A) Individual kinetics for SARS-CoV-2-S-reactive IFN-γ CD8⁺ T cells. (B) Individual kinetics for SARS-CoV-2-S-reactive IFN-γ CD4⁺ T cells. (C) Frequencies of SARS-CoV-2-Sreactive IFN-γ CD8⁺ and CD4+ T cells in nursing home residents with detectable responses at both baseline and follow-up. T cells. P-values for comparisons are shown (ns; not significant).

Recovered

Naïve

